|
gptkbp:instance_of
|
gptkb:depression
|
|
gptkbp:approves
|
gptkb:FDA
2006-12-20
|
|
gptkbp:atccode
|
N05 AX
|
|
gptkbp:brand
|
gptkb:Invega_Sustenna
gptkb:Invega_Trinza
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:contraindication
|
severe renal impairment
hypersensitivity to paliperidone
|
|
gptkbp:dosage_form
|
extended-release tablet
sustained-release injection
|
|
gptkbp:drug_interactions
|
CYP3 A4 inducers
CYP2 D6 inhibitors
|
|
gptkbp:duration
|
long-term
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:form
|
injection
oral tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Invega
|
|
gptkbp:ingredients
|
gptkb:paliperidone
|
|
gptkbp:invention
|
2023-12-31
|
|
gptkbp:is_monitored_by
|
gptkb:weight
blood sugar
lipid levels
|
|
gptkbp:legal_status
|
prescription only
|
|
gptkbp:lifespan
|
23 hours
|
|
gptkbp:manufacturer
|
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patient_population
|
adults
adolescents
|
|
gptkbp:pharmacokinetics
|
dopamine D2 receptor antagonist
serotonin 5-HT2 A receptor antagonist
|
|
gptkbp:related_to
|
gptkb:risperidone
|
|
gptkbp:route_of_administration
|
oral
intramuscular
|
|
gptkbp:side_effect
|
anxiety
nausea
drowsiness
insomnia
constipation
dry mouth
weight gain
blurred vision
tremors
increased heart rate
|
|
gptkbp:structure
|
C23 H27 Cl N2 O3 S
|
|
gptkbp:symptoms
|
anxiety
nausea
vomiting
irritability
insomnia
|
|
gptkbp:used_for
|
treatment of schizoaffective disorder
treatment of schizophrenia
|
|
gptkbp:bfsParent
|
gptkb:Janssen_Biotech
gptkb:Paliperidone
gptkb:Janssen_Research_&_Development
|
|
gptkbp:bfsLayer
|
6
|